With Clé, Ascléa GmbH is developing a platform that enables hospitals to use modern language models and agentic AI under their own sovereign control — either in their own data center or via European sovereign cloud providers. Building on this, existing clinical IT systems will be integrated into Clé to make relevant data usable for AI applications.

"Over the past years, x-cardiac allowed us to build up special expertise that we now want to apply on a larger scale. With Clé we have reached an important first milestone, and further ones will follow soon. With the funds from the completed financing round, Ascléa is now in a position to realize this vision," says CEO Oliver Höppner.

"The healthcare market is facing major challenges. AI can provide essential support here in maintaining the performance of our clinical landscape, taking over tasks that tie up staff resources without directly serving patient care. Clé opens up a wide range of possibilities for using AI in everyday clinical practice," explains Chief Medical Officer Prof. Dr. med. Alexander Meyer.

Over the past years, x-cardiac has established itself as a pioneer in AI-based medical devices for predicting postoperative complications following cardiac surgery procedures. With the expansion of the product portfolio, this AI expertise and experience will be made even more broadly accessible going forward.

About Ascléa GmbH

Ascléa is a leading company in the field of digital health solutions and a spin-off of the German Heart Center at Charité and Charité – Universitätsmedizin Berlin. The company already has two CE-certified AI-based medical devices on the market and uses AI technologies to automate knowledge work in hospitals, thereby supporting better care. For more information, visit www.asclea.ai.

Contact:
Oliver Höppner
Ascléa GmbH
presse@asclea.ai

About IBB Ventures

Since 1997, IBB Ventures has provided venture capital for innovative Berlin-based companies and is one of the most active players in early-stage financing in Berlin. In addition to its two VC funds for technology and creative companies with a total volume of €100 million, as well as the Impact VC Fund established in 2022 with €30 million, the €10 million pre-seed fund B# ("be sharp") for Berlin deep-tech startups, launched in 2025, is also currently in its investment phase. The funds are financed through the European Regional Development Fund (ERDF) and Investitionsbank Berlin (IBB).

IBB Ventures has already invested in around 310 Berlin-based companies. Through consortia with partners, these startups have received more than €2.1 billion, of which IBB Ventures has invested more than €320 million as lead, co-lead, or co-investor. IBB Ventures is the umbrella brand for the VC activities of IBB Beteiligungsgesellschaft and part of the IBB Group. www.ibbventures.de

Contact:
Christian Seegers
IBB Ventures
Bundesallee 210
10719 Berlin
Tel: +49 (0)30 2125 3201
Email: info@ibbventures.de